Closely-held Zucara Therapeutics is expanding the development of ZT-01, which is currently in a Phase 1 trial for the prevention of insulin-induced hypoglycemia in patients with Type 1 Diabetes (T1D), to Type 2 Diabetes (T2D).
ZT-01’s development for T2D will be partly supported by advisory services and up to $415,000 in R&D funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), which previously awarded the company with up to $400,000 for ZT-01’s development for T1D.
In addition, Zucara and York University have been awarded a Mitacs Accelerate Fellowship grant, which will fund the development of a preclinical T2D model.
“The expansion of our ZT-01 development program is based on promising results in a preclinical model of T2D and represents the potential to benefit a substantially larger population,” Dr. Richard Liggins, Zucara’s CSO, said in a statement.
“We look forward to working with York University to advance this preclinical T2D model to enable future clinical development,” he added.
